- Home
- ROIV vs AES Comparison
ROIV vs AES Comparison
Compare ROIV & AES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- AES
- Stock Information
- Founded
- ROIV 2014
- AES 1981
- Country
- ROIV United Kingdom
- AES United States
- Employees
- ROIV N/A
- AES N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- AES Electric Utilities: Central
- Sector
- ROIV Health Care
- AES Utilities
- Exchange
- ROIV Nasdaq
- AES Nasdaq
- Market Cap
- ROIV 7.8B
- AES 7.1B
- IPO Year
- ROIV N/A
- AES 1991
- Fundamental
- Price
- ROIV $11.45
- AES $10.41
- Analyst Decision
- ROIV Buy
- AES Hold
- Analyst Count
- ROIV 4
- AES 8
- Target Price
- ROIV $17.50
- AES $12.71
- AVG Volume (30 Days)
- ROIV 5.4M
- AES 16.4M
- Earning Date
- ROIV 08-07-2025
- AES 07-31-2025
- Dividend Yield
- ROIV N/A
- AES 6.71%
- EPS Growth
- ROIV N/A
- AES 146.43
- EPS
- ROIV N/A
- AES 1.83
- Revenue
- ROIV $29,053,000.00
- AES $12,119,000,000.00
- Revenue This Year
- ROIV $2.64
- AES $3.95
- Revenue Next Year
- ROIV $378.09
- AES $2.93
- P/E Ratio
- ROIV N/A
- AES $5.74
- Revenue Growth
- ROIV N/A
- AES N/A
- 52 Week Low
- ROIV $8.73
- AES $9.46
- 52 Week High
- ROIV $13.06
- AES $20.30
- Technical
- Relative Strength Index (RSI)
- ROIV 57.83
- AES 44.02
- Support Level
- ROIV $10.89
- AES $10.40
- Resistance Level
- ROIV $11.79
- AES $11.73
- Average True Range (ATR)
- ROIV 0.35
- AES 0.42
- MACD
- ROIV 0.01
- AES -0.02
- Stochastic Oscillator
- ROIV 62.57
- AES 25.02
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About AES The AES Corporation
AES is a global power company that operates in 15 countries. Its generation portfolio as of year-end 2023 totals over 35 gigawatts, including renewable energy (53%), gas (27%), coal (18%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.